Alendronate Treatment Duration and Drug Holiday Criteria
For oral alendronate, reassess fracture risk after 5 years of treatment and consider a drug holiday for patients at low-to-moderate fracture risk, while continuing therapy for those who remain at high risk. 1, 2, 3
Initial Treatment Duration
Alendronate should be administered for an initial period of 3-5 years before reassessing the need for continued therapy 1, 2. The FDA label explicitly states that the optimal duration has not been determined, but all patients should have their need for continued therapy re-evaluated periodically, with consideration for drug discontinuation after 3-5 years in low-risk patients 3.
Criteria for Drug Holiday
Patients Eligible for Drug Holiday (after 5 years):
- T-score > -2.5 at femoral neck or hip
- No fractures during treatment period
- Low-to-moderate fracture risk on reassessment 1, 2
Patients Who Should Continue Treatment:
- T-score ≤ -2.5 at femoral neck
- History of vertebral fractures (especially severe or multiple)
- Prior hip fracture
- Very high fracture risk indicators: advanced age, frailty, glucocorticoid use, very low T-scores, increased fall risk 2
For very high-risk patients, treatment can be extended for up to 10 years total (6-10 years of stability) before considering a drug holiday 2.
Drug Holiday Management
A bisphosphonate holiday is defined as temporary discontinuation for up to 5 years 1. The evidence supporting residual antifracture effects during holidays is stronger for alendronate and zoledronic acid due to their bone retention properties 1.
During the Holiday - Reassess Every 2-4 Years:
- BMD decline beyond the least significant change (LSC) of the DXA machine
- New fracture occurrence
- Bone turnover markers rising to pretreatment values
- Changes in clinical risk factors 1, 2
Resume Treatment If:
- Any fracture occurs
- BMD declines significantly (beyond LSC)
- Bone turnover markers increase substantially
- Patient again meets initial treatment criteria 2
Important Clinical Nuances
The 2019 Endocrine Society guideline 1 and 2020 AACE guideline 2 represent the most authoritative and recent recommendations, both emphasizing individualized risk assessment at 3-5 years. The AACE guideline provides the most specific algorithm: after 5 years of oral bisphosphonates, patients with T-scores > -2.5 or who remained fracture-free can consider a holiday, while high-risk patients continue treatment 2.
Critical distinction: This drug holiday strategy applies only to bisphosphonates (particularly alendronate and zoledronic acid) due to their prolonged skeletal retention. Drug holidays are not recommended for denosumab, raloxifene, or other non-bisphosphonate agents, as these lack residual effects after discontinuation 1, 2. Denosumab discontinuation specifically requires transition to another antiresorptive to prevent rebound bone loss and vertebral fractures 1, 2.
The balance of benefits versus rare harms (atypical femoral fractures, osteonecrosis of the jaw) favors continued treatment in high-risk patients but supports holidays in lower-risk patients after 5 years 1, 4. Research suggests that treating 1000 osteoporotic women with bisphosphonates for 3 years prevents 100 fractures while causing approximately 0.08-0.1 atypical femoral fractures 1.
For younger postmenopausal women (ages 50-70) initiating treatment, a 5-year treatment period followed by drug holiday is generally more cost-effective, whereas older women (age 80+) may benefit from 10 years of treatment before considering a holiday 5.